1-2 of 2
Anjali Vaze
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

Alex F. Herrera, Manish R. Patel, John M. Burke, Ranjana Advani, Bruce D. Cheson, Jeff P. Sharman, Elicia Penuel, Andrew G. Polson, Chen Di Liao, Chunze Li, Eva Schuth, Anjali Vaze, Divya Samineni, Rebecca Elstrom, James Cooper, Catherine Diefenbach
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1294–1301.
https://doi.org/10.1158/1078-0432.CCR-21-3261
Published: 01 April 2022
View article titled, Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study
Open the PDF for Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study in another window
Includes: Supplementary data
Journal Articles

Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

David E. Gerber, Jeffrey R. Infante, Michael S. Gordon, Sarah B. Goldberg, Miguel Martín, Enriqueta Felip, Maria Martinez Garcia, Joan H. Schiller, David R. Spigel, Julie Cordova, Valerie Westcott, Yulei Wang, David S. Shames, YounJeong Choi, Robert Kahn, Randall C. Dere, Divya Samineni, Jian Xu, Kedan Lin, Katie Wood, Stephanie Royer-Joo, Vanessa Lemahieu, Eva Schuth, Anjali Vaze, Daniel Maslyar, Eric W. Humke, Howard A. Burris, III
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (2): 364–372.
https://doi.org/10.1158/1078-0432.CCR-18-3965
Published: 15 January 2020
View article titled, Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Open the PDF for Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer in another window
Includes: Supplementary data